{
  "id": 3532044,
  "title": "Moderna Drops 7% Despite a Fresh Wolfe Research Upgrade, BioNTech Slips",
  "url": "https://urgent.news/2026/08/26/moderna-drops-7-despite-a-fresh-wolfe-research-upgrade-biontech-slips",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-26T15:25:38.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/moderna-drops-7-despite-fresh-152538054.html"
  },
  "original_language": "en",
  "account": "Moderna's stock dropped 7% following a fresh upgrade from Wolfe Research, while BioNTech's stock slipped 2%, suggesting the selloff is specific to Moderna. Despite this, the broader biotech sector remains relatively stable, with the iShares Biotechnology ETF barely moving. Moderna's valuation of $59.09 billion is questioned, as it includes an unapproved drug program with no current revenue. However, Wolfe Research maintains a positive outlook, estimating potential sales of $9.2 billion for the company's intismeran program. Moderna's stock showed significant growth in the past year, with a 439% increase, but the recent 7% drop appears to be profit-taking after a substantial rally. The company reported a net loss of $1.97 per share in Q2 2026, but revenue grew 2.1% year-over-year. Key partners in Moderna's intismeran program include Merck and KEYTRUDA.",
  "summary": null,
  "key_points": [
    "Moderna's stock fell 7% following Wolfe Research's upgrade.",
    "BioNTech's stock dropped 2%, indicating the decline is specific to Moderna.",
    "iShares Biotechnology ETF remained stable despite the biotech sector's fluctuations."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}